On 6 December 2022, the Shanghai MicroPort MedBot (Group) Co., Ltd. and MicroPort Scientific Corporation entered into the Sales Framework Agreement, pursuant to which, the Group agreed to sell and the MicroPort Group agreed to purchase the Products, for the purposes of the commercialization and distribution of the Products in the relevant target markets, which includes (i) surgical robot equipment (namely Honghu); and (ii) surgical robot equipment supporting accessories and consumables. The term of the Sales Framework Agreement commences upon the obtaining the Independent Shareholders' approval at the EGM or from 1 January 2023 (whichever is the later) to 31 December 2025 (both days inclusive). Pursuant to the Sales Framework Agreement, the MicroPort Group was engaged to commercialise, market and sell the Products in the relevant target markets.

All the Products will be sold to the MicroPort Group directly without involving any dealers under Sales Framework Agreement. Apart from the Final Price (as defined below), the MicroPort Group will not receive any further commission or distribution fee pursuant to the Sales Framework Agreement. In order to ensure the transactions conducted under the Sales Framework Agreement are on normal commercial terms, the Company will take into account the market data obtained from Frost & Sullivan in the relevant target markets to determine the pricing policy for the Products.

As a general principle, the prices to be charged by the Group under the Sales Framework Agreement for the sale of the Products will be determined in accordance with the following pricing principles.